Présentations scientifiques

12

Déc 2023
15:49 E.S.T.

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T-Cell Product Manufactured by Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ (B-ALL) – ASH 2023 – Présentation Poster

Télécharger le PDF

12

Déc 2023
15:47 E.S.T.

Preliminary Results of NatHaLi-01: A First-In-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL) – ASH 2023 – Présentation Poster

Télécharger le PDF

5

Nov 2023
20:17 E.S.T.

TGFBR2 KO combined with activation-induced IL12 secretion synergize to optimize potency and safety of MUC1-CAR T-cells in preclinical targeting of triple-negative breast cancer – SITC – Présentation Poster

Télécharger le PDF

27

Oct 2023
08:42 E.S.T.

Comprehensive Analysis of the Editing Window of TALE Base Editors – ESGCT 2023 – Présentation Poster

Télécharger le PDF

27

Oct 2023
08:39 E.S.T.

Intronic editing enables lineage-specific expression of therapeutics relevant for HSPC gene therapy – ESGCT 2023 – Présentation Poster

Télécharger le PDF

27

Oct 2023
08:37 E.S.T.

Non-Viral DNA Delivery Coupled To TALEN Gene Editing Efficiently Correct The Sickle Cell Mutation In Long-Term HSCS – ESGCT 2023 – Présentation Poster

Télécharger le PDF

22

Sep 2023
13:08 E.S.T.

TALEN®-Edited Inducible Dual Car T-Cells Aimed at Safe and Effective Targeting Of Solid Tumors – CICON 2023 – Présentation Poster

Télécharger le PDF

8

Juin 2023
08:25 E.S.T.

Updated Results of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR T-cell Product, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) – EHA 2023 – Présentation Poster

Télécharger le PDF

5

Juin 2023
10:54 E.S.T.

UCART20x22: allogeneic dual CAR T-cells for the treatment of B-cell malignancies – ISCT 2023 – Présentation orale

Télécharger le PDF

5

Juin 2023
07:30 E.S.T.

Comprehensive Analysis of the Editing Window of TALE Base Editors – ISCT 2023 – Présentation poster

Télécharger le PDF

Présentations scientifiques

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T-Cell Product Manufactured by Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ (B-ALL) – ASH 2023 – Présentation Poster

Preliminary Results of NatHaLi-01: A First-In-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL) – ASH 2023 – Présentation Poster

TGFBR2 KO combined with activation-induced IL12 secretion synergize to optimize potency and safety of MUC1-CAR T-cells in preclinical targeting of triple-negative breast cancer – SITC – Présentation Poster

Comprehensive Analysis of the Editing Window of TALE Base Editors – ESGCT 2023 – Présentation Poster

Intronic editing enables lineage-specific expression of therapeutics relevant for HSPC gene therapy – ESGCT 2023 – Présentation Poster

Non-Viral DNA Delivery Coupled To TALEN Gene Editing Efficiently Correct The Sickle Cell Mutation In Long-Term HSCS – ESGCT 2023 – Présentation Poster

TALEN®-Edited Inducible Dual Car T-Cells Aimed at Safe and Effective Targeting Of Solid Tumors – CICON 2023 – Présentation Poster

Updated Results of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR T-cell Product, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) – EHA 2023 – Présentation Poster

UCART20x22: allogeneic dual CAR T-cells for the treatment of B-cell malignancies – ISCT 2023 – Présentation orale

Comprehensive Analysis of the Editing Window of TALE Base Editors – ISCT 2023 – Présentation poster

Scientific publications